- À propos de nous
- Qualité et durabilité
- Actualité & nouvelles
- Point of Care
- Oncology Testing
- Research & Industry
- Service technique
- Contrôle de qualité & Service en ligne
- Centre de documents & téléchargement
- Centre d’expertise
- Clinique & Laboratoire
- Formation et qualification
Select your local website
Haemostasis is a complex process that helps to keep the blood in a fluid state and prevent blood loss at the site of injury. While the intact endothelium of blood vessels has an anti-thrombogenic function that prevents blood coagulation, in the case of vessel wall damage, the exposed sub-endothelial components initiate the formation of a clot that will stop blood loss.
Blast cells – a diagnostic heavyweight
The detection of blast cells in the peripheral blood is considered extremely important, and great responsibility is placed on the investigating laboratory. As well as informa¬tion on the physiology, this SEED article describes the possible causes of the release of blast cells into the blood, the char¬acteristics by which they can be identified and how further diagnosis is carried out.
- Xtra Article
Counting of highly fluorescent lymphocytes (HFLC) as antibody-producing plasma cells on XE-5000
Besides the IG there is a distinct separation of an abnormal cell population with high fluorescence intensity above the monocyte and lymphocyte region. Highly fluorescent lymphocyte cells (HFLC) are observed in the DIFF channel of the Sysmex XE-series haematology analysers in an area of high fluorescence intensity.
- White Paper
Differential diagnosis of thrombocytopenia
Determining the aetiology of thrombocytopenia is of major importance. The immature platelet fraction (IPF) can help you promptly differentiate between ineffective bone marrow production and increased destruction or consumption of platelets. Find out more about the use of this parameter here.
- White Paper
- Analyse d´urine
Fighting the burden of chronic kidney disease by frequent albuminuria screening in risk group patients
Chronic kidney disease (CKD) is a severe complication in context of various civilisation diseases, such as diabetes, hypertension, and obesity. With increasing treatment cost along the progression of CKD towards end-stage renal failure (ESRF) and the need for renal replacement therapies, CKD is not only a driver of premature mortality and diminished quality of life of affected individuals, but also puts significant burden on the society and healthcare expenditures. The early detection of kidney damage through a frequent screening of risk patients could help to fight the burden of CKD. Cost-efficient routine urinalysis data could play a vital role in providing valuable information for screening, diagnosing, and monitoring of renal disorders.